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Abstract
Background: Since circulating levels of TNF-related apoptosis inducing ligand (TRAIL) may be important in the
physiopathology of pregnancy, we tested the hypothesis that TRAIL levels change at delivery in response to stressful
conditions.
Methods/Principal Findings: We conducted a longitudinal study in a cohort of 73 women examined at week 12, week 16,
delivery and in the corresponding cord blood (CB). Serum TRAIL was assessed in relationship with maternal characteristics
and to biochemical parameters. TRAIL did not vary between 12 (67.6627.6 pg/ml, means6SD) and 16 (64.0616.2 pg/ml)
weeks’ gestation, while displaying a significant decline after partum (49.3626.4 pg/ml). Using a cut-off decline .20 pg/ml
between week 12 and delivery, the subset of women with the higher decline of circulating TRAIL (41.7%) showed the
following characteristics: i) nullipara, ii) higher age, iii) operational vaginal delivery or urgent CS, iv) did not receive analgesia
during labor, v) induced labor. CB TRAIL was significantly higher (131.6652 pg/ml) with respect to the corresponding
maternal TRAIL, and the variables significantly associated with the first quartile of CB TRAIL (,90 pg/ml) were higher pre-
pregnancy BMI, induction of labor and fetal distress. With respect to the biochemical parameters, maternal TRAIL at delivery
showed an inverse correlation with C-reactive protein (CRP), total cortisol, glycemia and insulin at bivariate analysis, but only
with CRP at multivariate analysis.
Conclusions: Stressful partum conditions and elevated CRP levels are associated with a decrease of circulating TRAIL.
Citation: Zauli G, Monasta L, Rimondi E, Vecchi Brumatti L, Radillo O, et al. (2011) Circulating TRAIL Shows a Significant Post-Partum Decline Associated to
Stressful Conditions. PLoS ONE 6(12): e27011. doi:10.1371/journal.pone.0027011
Editor: Haibin Wang, State Key Laboratory of Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, China
Received June 24, 2011; Accepted October 8, 2011; Published December 14, 2011
Copyright:  2011 Zauli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by CRTrieste foundation (to GZ) and Associazione Amici del Cuore. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: paola.secchiero@unife.it
. These authors contributed equally to this work.
Introduction
TNF-related apoptosis inducing ligand (TRAIL) is a TNF
family member expressed as either a type II transmembrane
protein or, similarly to other membrane-bound ligands of the TNF
superfamily, as a soluble protein, which is detectable in the serum
under physiological conditions [1]. Although the best character-
ized biological activity of TRAIL, also known as Apo2 ligand, is
represented by a potent induction of apoptosis in a variety of
cancer cell types [2], the wide expression of TRAIL and TRAIL
receptors in many normal tissues suggests that the physiological
role of TRAIL is more complex than merely activating the
apoptotic pathway in cancer cells. Indeed, accumulating evidence
suggests possible non-apoptotic functions regulated by TRAIL [3]
and, in particular, by soluble TRAIL, which is able to activate
intracellular signal transduction pathways involved in cell survival,
migration and proliferation in a variety of normal cells [3]. These
biological activities of soluble TRAIL are observed at concentra-
tions (10–100 pg/ml) in the range found in serum/plasma [4–10].
Among different tissues, it is noteworthy that TRAIL and its
receptors are abundantly expressed in the human placenta [11–
14], where TRAIL has been proposed to contribute to the
establishment of immune privilege during pregnancy [11,12]. In
addition, soluble TRAIL displays regulatory effects on endothelial
cells and more in general on the vascular system [15–18]. While
there are data regarding the serum level of the TRAIL receptor
osteoprotegerin (OPG) [19] during pregnancy [20], anything is
known about potential modulation of circulating soluble TRAIL
concentrations from early pregnancy to post-partum after labor.
On these bases, the aim of the present study was to measure the
serum levels of TRAIL in a cohort of women, at early time points of
pregnancy (12 and 16 weeks), at the delivery, as well in the respective
umbilical cord blood (CB), in order to assess: i) the relationship between
TRAIL and clinical and biochemical parameters, ii) the relationship
between the maternal and CB levels of circulating TRAIL.
Materials and Methods
Study population
The study population consisted of 73 women who underwent
amniocentesis. The procedures followed were in accordance with
the Declaration of Helsinki and approved by the institutional
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Burlo Garofolo of Trieste). All participant subjects gave written
informed consent. Serial blood samples were obtained from each
woman at 12 (time 1) and 16 (time 2) weeks’ gestation and within
15 minutes post-partum (time 3). In addition, blood samples were
collected as umbilical mixed arterial-venous CB samples at
delivery. The samples were immediately centrifuged, aliquoted
and the sera were frozen at 280uC until biochemical measure-
ments.
The main characteristics of the 73 women are reported in
Table 1 and include: i) maternal data, such as maternal age at
delivery, pre-gestational BMI (body mass index), ethnicity, parity,
pregnancy, type of conception, smoking at 12 weeks’ gestation,
pathological course of pregnancy, gestational hypertensive disor-
ders, gestational diabetes, karyotyping, fetal growth restriction
during pregnancy; ii) delivery data, such as gestational age at
delivery, induction of labor, delivery modality, such as spontane-
ous vaginal, operative vaginal, elective cesarean section (CS),
urgent CS, analgesia during labor; iii) neonatal outcome: live
births, cord blood pH and base excess (BE), Apgar at 1
st and 5
th
minute, need of resuscitation in first 30 minutes after delivery,
need of admission to intensive neonatal care, fetal distress.
Demographic and clinical characteristics were ascertained from
baseline interview, medical records/database and/or clinical
medical examination. For some of the parameters reported in
Table 1 and analyzed in Table S1, we had some missing data:
when the number of observation is less than 73 women, the
number of observation is specified in Tables 1.
Biochemical measurements
For the measurement of circulating TRAIL, analyses were
performed in duplicate by using specific, commercially available
ELISA kit (R&D Systems, Minneapolis, MN) in accordance with
the manufacturer’s instructions and analyzed with an ELISA
reader at 450 nm, as previously described [21]. Standard curves
were set up by using scalar dilution series of the recombinant
human proteins (TRAIL) provided by the manufacturers as
standard for each specific kit. Sensitivity of the assay was 2.86 pg/
ml and the intra- and inter-assay coefficients of variation (CV)
were 3.9% and 6% respectively, and the upper limit of detection
was 1000 pg/ml. Selected serum samples were run in each ELISA
plate, as internal controls, confirming the reproducibility of the
determinations over times.
Total cortisol and insulin levels were measured by Cobas
Modular E analyzer (Roche Diagnostics, Basel, Switzerland) with
electrochemiluminescence assay following manufacturer’s instruc-
tions. For total cortisol, sensitivity of the assay was 0.018 mg/dl
and the intra- and inter-assay CV were 1.3% and 2.89%
respectively, and the upper limit of detection was 63.4 mg/dl.
For insulin, sensitivity of the assay was 0.200 mU/ml and the intra-
and inter-assay CV were 1.9% and 2.7% respectively, and the
upper limit of detection was 1000 mU/ml. CRP levels were
determined on Cobas Modular P analyzer (CRPL3 Tina-quant C-
Reactive Protein Gen. 3 by Roche Diagnostics) immunoturbidi-
metric method following manufacturer’s instructions. For CRP
sensitivity of the assay was 0.03 mg/dl and the intra- and inter-
assay CV were 1.3% and 2.43% respectively, and the upper limit
of detection was 35 mg/dl. Serum glucose was measured by Cobas
Modular A analyzer (Roche Diagnostics) with enzymatic methods
following manufacturer’s instructions. Sensitivity of the assay was
2 mg/dl and the intra- and inter-assay CV were 1.0% and 1.7%,
respectively and the upper limit of detection was 750 mg/dl. All
biochemical markers were determined in duplicate and were run
in the same assay in each period.
Statistical analyses
The differences among the TRAIL, total cortisol, glucose,
insulin, CRP values across study phases were measured with the
non-parametric Friedman test for matched samples. A post-hoc
test, the non-parametric Wilcoxon signed-rank test, was then
applied with Bonferroni adjustment for the number of one to one
comparisons. Correlations between TRAIL and variables were
estimated using Spearman’s correlation coefficient.
A bivariate analysis was conducted to study the relation between
difference in TRAIL values between time 1 and time 3 (higher
than 20 pg) and variables related to maternal characteristics,
delivery and neonatal outcomes, illustrated in Table 1. P values
were calculated using the Mann-Whitney non parametric test in
case of continuous variables and the two tailed Fisher exact test in
case of dichotomous variables. Multivariate logistic regression
analyses were run with TRAIL (either from maternal measure-
ments or CB values, as detailed in the Results section) and
including as potential predicting variables those related to
maternal characteristics, pregnancy, delivery and neonatal out-
comes. The logistic regression also considered the levels of CPR
(#0.5 vs. .0.5 mg/dl for maternal blood and #0.35 vs. .0.35 for
CB) and total cortisol, insulin, and glucose (expressed as quartiles)
at delivery and into the CB. Stata/IC 11.2 was used for the
analyses (StataCorp LP, College Station, USA; www.stat.com). A
two-sided p-value ,0.05 has been chosen as statistically
significant.
Results
The circulating levels of maternal TRAIL are significantly
decreased immediately after partum
In Table 1 we report the results of the descriptive analysis.
Maternal age appears to be quite high due to the nature of our
study, which focused on women who would accept to carry out
amniocentesis. In our group of 73 women, 48% were nulliparous,
four were obese (BMI$30), two conceived with artificial methods,
two were not Caucasian, two smoked during pregnancy (smoked
at 12 weeks gestation). All women had a normal karyotype, while
12 had a pathological course of pregnancy.
For each subject, the serum levels of TRAIL were measured in 2
different time points of the gestational period (time 1: 12 weeks,
time 2: 16 weeks), at the partum (time 3) as well as in the serum
derived from the corresponding CB. As shown in Figure 1A, the
values of circulating soluble TRAIL were not significantly different
between time 1 and time 2 (p=0.703), while they showed a clear
decrease at delivery (p,0.01). The non-parametric Friedman test
for matched samples on the three values has a p,0.001. The
Wilcoxon signed-rank test with Bonferroni correction for multiple
comparisons (three comparisons: significant if p,0.017) showed
significant differences between TRAIL measures at time 1 and
time 3 (p,0.001), and between measures at time 2 and time 3
(p,0.001). On the other hand, the circulating TRAIL levels in the
umbilical CB were significantly higher than the maternal levels
examined in the different time points (in all cases p,0.0001).
By analyzing the kinetics of TRAIL at different time points, two
groups of women could be identified: one group included women
characterized by either no significant decrease or (in 7 cases) by an
increase of TRAIL (Figure 1B, upper panel), while in the second
group a clear-cut decline was observed (Figure 1B, lower panel).
In particular, a subset of women (41.7%) had a decrease in TRAIL
from time 1 to time 3 .20 pg/ml, showing a decrease in the levels
of circulating TRAIL similar to that previously observed in
patients affected by coronary artery disease [5–9].
Post-Partum Decline of TRAIL
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In the bivariate analysis for the study of the factors associated with
the outcome ‘‘TRAIL at time 1 - TRAIL at time 3’’ .20 pg/ml, it was
observed that the women more at risk of a significant decrease in
TRAIL at the partum were those: with higher age, nulliparous, with
induction of labor, with operative vaginal delivery or urgent CS, who
did not have analgesia during labor or with fetal distress (Table S1). A
multivariate logistic regression analysis was run with the above
mentioned outcome and including as potential predicting variables
only those related to maternal characteristics, pregnancy and delivery,
as reported in Table 1.W ee x c l u d e dt y p eo fc o n c e p t i o nf r o mt h e
multivariate logistic regression model because no women had an
artificial conception in the group with reduction of TRAIL values
#20 pg/ml. In multivariate logistic regression analysis (Table 2), the
variables significantly (p,0.05) associated with the outcome are the
following: higher maternal age at delivery, no analgesia during labor,
nulliparity, induction of labor, operative vaginal delivery or urgent CS.
Maternal conditions and fetal distress also affect CB
TRAIL levels
In the next group of experiments, we sought to investigate
whether the maternal characteristics, which are associated with the
decline of maternal TRAIL at delivery, also affected CB TRAIL.
For this purpose, in the absence of references for normal/
pathological levels of funicular TRAIL, we decided to adopt the
cut-off identifying 25% of sample with the lowest levels of funicular
TRAIL. Given the size of the sample, 25% guaranteed a good size
in the affected group to allow detection of possible associations
with other factors. In a multivariate logistic regression model with
the first quartile of CB TRAIL as outcome (0 if $90 pg/ml, 1 if
,90 pg/ml), we could reconsider the variable on type of
conception and had to exclude, however, ethnicity, smoke and
diabetes mellitus because of collinearity. The variables significantly
associated with a CB TRAIL ,90 pg/ml were the following:
higher pre-pregnancy BMI, induction of labor and fetal distress
(Table 3).
Table 1. Main characteristics of the enrolled women*.
Characteristics Number (%) or Mean (±SD)
Maternal age at delivery (years) 37.9 (2.86SD)
Parity: Nulliparous/Pluriparous 35 (47.9%)/38 (52.1%)
Pre pregnancy BMI 22.9 (4.06SD)
BMI categories: BMI,30/BMI$30 69 (94.5%)/4 (5.5%)
Conception: Spontaneous/Artificial 71 (97.3%)/2 (2.7%)
Ethnicity: Caucasian/Other 71 (97.3%)/2 (2.7%)
Smoking at 12 weeks gestation: No/Yes 71 (97.3%)/2 (2.7%)
Pathological course of pregnancy: No/Yes 61 (83.6%)/12 (16.4%)
Gestational Hypertensive disorders: No/Yes 68 (93.2%)/5 (6.8%)
Diabetes: No 70 (95.9%)
Pregestational diabetes/Gestational diabetes 0 (0%)/3 (4.1%)
Karyotyping (n=67): Normal/Abnormal 67 (100%)/0 (0%)
Fetal growth restriction above 10%: No/Yes 41 (56.2%)/32 (43.8%)
Gestational age at delivery (weeks) 39 (1.56SD)
Induction of labor (n=72): No/Yes 59 (81.9%)/13 (18.1%)
Delivery modality:
- Spontaneous vaginal 54 (74.0%)
- Elective CS 6 (8.2%)
- Urgent CS 8 (11.0%)
- Operative vaginal 5 (6.8%)
Analgesia during labor: Yes/No 21 (30%)/50 (70%)
Delivery outcome: Live births 73 (100.0%)
Umbilical pH (n=62): pH$7.1/pH,7.1 60 (96.8%)/2 (3.2%)
Umbilical BE (n=60): BE$212/BE,212 59 (98.3%)/1 (1.7%)
Apgar 1
st minute: Apgar$5/Apgar,5 71 (97.3%)/2 (2.7%)
Apgar 5
th minute: Apgar$7/Apgar,7 72 (98.6%)/1 (1.4%)
Need of resuscitation in first 30 min. (n=71): No/Yes 69 (97.2%)/2 (2.8%)
Admission to Intensive Neonatal Care: No/Yes 65 (89%)/8 (11%)
Fetal distress: No/Yes 64 (88%)/9 (12%)
*n=73 unless specified. SD: standard deviance; BMI: Body Mass Index; CS: caesarean section; BE: base excess.
doi:10.1371/journal.pone.0027011.t001
Post-Partum Decline of TRAIL
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Since the data illustrated above suggested that stressful
conditions might be involved in mediating the decline of TRAIL
observed at delivery and might also influence CB TRAIL levels,
we have then investigated the potential correlation between levels
of circulating TRAIL and relevant biochemical parameters, such
as total cortisol, glycemia, insulinemia and CRP. In particular,
CRP was included since previous studies have shown that it
increases during pregnancy under both normal and pathological
conditions [22–25]. As reported in Figure 2 and Table S2, the
levels of total cortisol, glycemia, insulin and CRP showed a
significant increase at the delivery (time 3) with respect to the
previous time points analyzed (time 1 and/or time 2). In
particular, while insulin and total cortisol showed a progressive
increase from time 1 to time 3 (Figure 2 and Table S2), glycemia
and CRP showed a peak at delivery (Figure 2 and Table S2).
Moreover, while the levels of total cortisol glycemia and insulin in
CB were not significantly different from maternal values at times 1 Table 2. Multivariate logistic regression analysis of factors
associated with the outcome: TRAIL (T.1–T.3) .20 pg.
OR 95% CI p*
Maternal age at delivery 1.564 1.163–2.104 0.003
Pre pregnancy BMI 0.952 0.786–1.152 0.612
Nulliparity
- No ref -
- Yes 7.576 1.393–41.667 0.019
Ethnicity
- Caucasian ref -
- Other 138.004 0.264–72103.070 0.123
Smoke
- No ref -
- Yes 0.087 0.000–18.798 0.373
Gestational hypertensive disorders
- No ref -
- Yes 0.011 0.000–0.823 0.051
Gestational diabetes
- No ref -
- Yes 0.043 0.000–3.139 0.151
Pathological course of pregnancy
- No ref -
- Yes 34.079 0.844–1376.167 0.061
Induction of labor
- No ref -
- Yes 15.737 1.280–193.405 0.031
Delivery modality
- Spontaneous vaginal or elective CS ref
- Urgent CS or operative vaginal 6.783 1.021–45.069 0.048
Fetal growth restriction above 10%
- No ref -
- Yes 4.868 0.862–27.482 0.073
Analgesia during labor
- Yes ref
- No 9.346 1.709–50.549 0.010
Gestational age at delivery 1.818 0.955–3.464 0.069
n=70, Pseudo R2=0.425. OR: Odds Ratio; CI: Confidence Interval; *p
value,0.05 in bold; BMI: Body Mass Index; CS: caesarean section.
doi:10.1371/journal.pone.0027011.t002
Table 3. Multivariate logistic regression analysis of factors
associated with the outcome: cord blood TRAIL-first quartile.
OR 95% CI p*
Maternal age at delivery 0.982 0.740–1.303 0.899
Pre pregnancy BMI 0.742 0.560–0.985 0.039
Parity
- Nulliparous Ref -
- Pluriparous 2.52 0.478–13.228 0.276
Gestational hypertensive disorders
- No Ref -
- Yes 22.485 0.0.527–959.462 0.104
Pathological course of pregnancy
- No Ref -
- Yes 0.113 0.005–2.452 0.165
Induction of labor
- No Ref -
- Yes 15.505 1.931–124.457 0.010
Delivery modality
- Spontaneous vaginal or elective CS Ref -
- Urgent CS or operative vaginal 0.646 0.039–10.745 0.761
Foetal growth restriction above 10%
- No Ref -
- Yes 0.956 0.241–3.789 0.949
Analgesia during labor
- Yes Ref -
- No 0.954 0.198–4.587 0.953
Gestational age at delivery 0.905 0.518–1.582 0.726
Admission to Intensive Neonatal Care
- No Ref -
- Yes 0.522 0.039–7.050 0.625
Foetal distress
- No Ref -
- Yes 37.091 0.979–1405.412 0.049
n=69, Pseudo R2=0.234. OR: Odds Ratio; CI: Confidence Interval; *p
value,0.05 in bold; BMI: Body Mass Index; CS: caesarean section.
doi:10.1371/journal.pone.0027011.t003
Figure 1. Serum TRAIL levels during pregnancy and in the corresponding cord blood. In A, levels of TRAIL were determined by ELISA in
sera from 73 pregnant women (analyzed at the indicated times of gestation and at delivery) and from the corresponding cord blood. Horizontal bars
are median, upper and lower edges of box are 75th and 25th percentiles, lines extending from box are 10th and 90th percentiles. In B, two groups of
women enrolled in this study were identified on the basis of the drop in the TRAIL serum levels between 12 weeks of gestation (time 1) and delivery
(time 3) ,20 pg/ml (group 1) or $20 pg/ml (group 2). Individual values for each of the 73 women are shown at time 1 and time 3.
doi:10.1371/journal.pone.0027011.g001
Post-Partum Decline of TRAIL
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very low as compared to maternal CRP values determined at
different time points (Figure 2 and Table S2). It is also
noteworthy that while the levels of maternal cortisol, glycemia and
insulin showed a significant positive correlation with CB cortisol,
glycemia and insulin (Table 4), no significant correlation was
observed between maternal (time 3) and CB levels of TRAIL
(R=0.032, p=0.792) nor between maternal and CB CRP
(Table 4). Of note, a significant inverse correlation was observed
between maternal TRAIL at delivery (time 3) and total cortisol,
TRAIL (time 3) and glycemia, TRAIL (time 3) and insulin as well
as between TRAIL (time 3) and CRP (Table 4 and Figure S1).
These findings were confirmed in a bivariate analysis with TRAIL
time 3-first quartile as outcome (data not shown). However, in a
multivariate logistic regression analysis with the outcome: TRAIL
time 3-first quartile, the only biochemical variable significantly
(p=0.003) associated with a TRAIL time 3-first quartile was CRP
(Table S3). On the other hand, glycemia, insulin and total cortisol
lost of significance with the only addition of another variable (data
not shown). The prominent association of CRP with maternal
TRAIL was further underlined by comparing the group of women
with reduction of TRAIL values #20 pg/ml vs the group with
reduction of TRAIL values .20 pg/ml, illustrated in Figure 1B,
for the levels of CRP at delivery. In fact, significantly (p,0.01)
higher levels of CRP (median 0.79, mean6SD 1.3961.60 mg/dl,
time 3) were measured in the group of women with reduction of
TRAIL values .20 pg/ml with respect to the other group
(median 0.47, mean6SD 0.5760.45 mg/dl, time 3).
Finally, when considering CB TRAIL, no correlations were
observed between CB TRAIL and CB levels of total cortisol,
glycemia, insulin and CRP (data not shown). Interestingly, when
CB serum samples were subdivided on the basis of the pathological
levels of glycemia (.96 mg/dl), insulin (.20 mU/ml), CRP
(.0.035 mg/dl), total cortisol (.17 mg/ml), CB TRAIL levels
tended to be lower in patients with high levels of total cortisol
compared to those with normal levels of cortisol (p=0.08), while
no significant differences were noticed in CB samples with
different levels of glycemia, insulin or CRP (Figure S2).
Figure 2. Changes in the serum levels of biochemical markers during pregnancy and in the corresponding cord blood. Serum levels
of (A) total cortisol, (B) glycemia, (C) insulin, (D) CRP were determined by ELISA in sera from 73 pregnant women (analyzed at the indicated times of
gestation and at delivery) and from the corresponding cord blood. Horizontal bars are median, upper and lower edges of box are 75th and 25th
percentiles, lines extending from box are 10th and 90th percentiles.
doi:10.1371/journal.pone.0027011.g002
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In this study, we have demonstrated for the first time that the
circulating levels of soluble TRAIL are significantly decreased at
delivery as compared to week 12 and week 16 of gestation in a
group of 73 women. A subset of these women (41.7%) had a
decrease in TRAIL at delivery .20 pg/ml with respect to the
levels observed at week 12. Interestingly, a comparable drop in the
levels of circulating TRAIL was previously observed in patients
affected by acute coronary artery disease [5–9], a finding that led
us and other Authors to hypothesize that TRAIL might have a
vasoprotective activity. In keeping with the idea that physiological
levels of circulating TRAIL has trophic effects on the blood vessels
[15–18], we have demonstrated for the first time that the soluble
TRAIL levels in CB were much greater than those found in their
mothers as well as in the general adult population [21]. In
addition, while the levels of total cortisol and glycemia and to a
lesser extent insulin showed a significant positive correlation
between maternal blood at delivery (time 3) and CB, no such
correlation was observed for TRAIL. This lack of correlation
between maternal and CB, together with the fact that TRAIL
levels were much higher in CB than in maternal blood strongly
suggests that TRAIL is autonomously produced also by fetal
tissues or annexes. In this respect, although no information is
currently available concerning the cellular source(s) of circulating
TRAIL in adults, it is noteworthy that several studies have
documented the presence of TRAIL, as well as of its receptors, in
human placenta [11–14,26–31]. The syncytiotrophoblast, cyto-
trophoblast, stromal cells and the capillary endothelium cells in
human placenta all appeared to be TRAIL immunoreactive [11–
14,26–31]. However, the potential contribution of placenta for
explaining both the differences between maternal and CB levels of
TRAIL, as well as the drop of circulating TRAIL after delivery,
remain to be established. In addition, further studies are required
in order to evaluate whether TRAIL is suitable to be a marker of
the health of the placenta and/or uteri during pregnancy.
Another important conclusion of our study was that a woman is
more at risk of a decrease .20 pg in TRAIL between 12 weeks
gestation and delivery if she is older, if she has an operational
vaginal delivery or an urgent CS, if she does not receive analgesia
during labor and if her labor is induced, as evaluated by
dichotomous and multivariate regression analyses. In addition,
by generating a dichotomous variable below or above 90 pg/ml in
the CB (first quartile), it was possible to demonstrate that levels of
TRAIL below 90 pg/ml in the CB were associated to higher pre-
pregnancy BMI, induction of labor and fetal distress. Thus, all
stressful conditions linked to partum modalities induced a
significant drop in the levels of circulating TRAIL. This notion
was strengthened by the observation that circulating TRAIL at
delivery was inversely related with biochemical markers of stress,
such as elevated glycemia, insulin and total cortisol levels, which
reach the highest levels at delivery [32]. Interestingly, elevated
levels of total cortisol were associated with low levels of TRAIL
also in the CB although this association did not reach statistical
significance. In addition, a previous study demonstrated that
pathological levels of cortisol increase the circulating levels of
osteoprogerin, a neutralizing receptor for TRAIL [33]. In
relationship with the potential vasoprotective activity of TRAIL
[15–18], it remains to be established whether the drop of TRAIL
after partum associated to stressful conditions represents a risk for
future cardiovascular disease, which, anyhow, is rare at the age of
the women enrolled in our study. The original aim of the present
prospective study was focused on gestation/labor, and no follow-
up was planned for the enrolled women. In this respect, at least
several years follow-up would be necessary to verify the hypothesis
of an increased chance of cardiovascular disease in relation to
higher decline of TRAIL levels after delivery.
The last important conclusion of our study is the existence of a
strong inverse correlation between CRP and TRAIL. This inverse
relationship was observed both at the time of delivery as well as
considering the group of women with reduction of TRAIL values
#20 pg/ml. Moreover, while the inverse association between
TRAIL and total cortisol, TRAIL and glycemia and TRAIL and
insulin were lost in multivariate analysis considering all the
biochemical data, the only variable which showed a persistent
association with reduced levels of TRAIL was CRP. In this respect,
previous studies concerning the potential association of TRAIL and
CRP have been conflicting since TRAIL has been either positively
[34,35] or negatively [36,37] associated to CRP. Our current data
unequivocally show the existence of an inverse association between
CRP and TRAIL during pregnancy. In agreement with our data
showing an increase of CRP levels during pregnancy with a peak at
delivery, previous studies have also shown that CRP increases
during pregnancy under both normal and pathological conditions
[22–25]. Interestingly, it has been proposed that CRP level during
pregnancy is a predictor of increased atherogenesis in children [24],
a finding particularly interesting in light of the anti-atherosclerotic
activity of TRAIL [17,21,37,38].
Table 4. Correlation among the circulating levels of TRAIL and metabolic markers, as analyzed by Spearman Rank correlation Test.
Variables
TRAIL
Cord blood
Cortisol
(T.3)
Glucose
(T.3)
Insulin
(T.3)
CRP
(T.3)
TRAIL
(T.3)
R=0.032
p=0.792
R=20.388
p=0.001*
R=20.281
p=0.018*
R=20.239
p=0.045*
R=2345 p=0.003*
Cortisol
Cord blood
R=20.118
p=0.323
R=0.601
p=0.000*
R=0.485 p=0.000* R=0.476 p=0.000* R=0.230 p=0.054
Glucose
Cord blood
R=20.029
p=0.809
R=0.549
p=0.000*
R=0.765
p=0.000*
R=0.519 p=0.000* R=0.121 p=0.312
Insulin
Cord blood
R=20.119
p=0.325
R=0.182
p=0.132
R=0.294 p=0.014* R=0.316 p=0.008* R=0.586 p=0.000*
CRP
Cord blood
R=20.176
p=0.138
R=20.127 p=0.290 R=20.070 p=0.558 R=20.123 p=0.302 R=20.109 p=0.363
R, coefficient of correlation;
*, p,0.05.
doi:10.1371/journal.pone.0027011.t004
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PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e27011We are aware that an important limitation of this exploratory
analysis is the lack of a critical time point in the third trimester
approaching parturition. This does not allow to know how the
concentrations of circulating TRAIL change towards the end of
pregnancy. Although the available data suggest that reduced
circulating TRAIL level (compared to the level in early pregnancy)
is associated with stressful conditions, at the moment remains to be
defined whether the TRAIL level is already reduced prior to
parturition (and thus could be used as an indication of potentially
complicated deliveries), or if the TRAIL reduction is caused by
stressful conditions during delivery. In spite of these limitations,
this study demonstrated for the first time the existence of a
significant association between stressful labor conditions and
down-regulation of TRAIL after partum.
Supporting Information
Figure S1 Correlations between serum levels of TRAIL
and biochemical markers measured at delivery. Inverse
correlation between serum levels of TRAIL and cortisol (A),
between TRAIL and glucose (B), between TRAIL and Insulin (C)
and between TRAIL and CRP (D) in women at the moment of
delivery (T.3). Correlation coefficient (R) and p values are
indicated.
(TIF)
Figure S2 Serum TRAIL levels with respect to cortisol
measured in cord blood. Serum levels of TRAIL were
analyzed in cord blood samples divided based on either low
(normal) or high (17 mg/dl) levels of total cortisol. Horizontal bars
are median, upper and lower edges of box are 75th and 25th
percentiles, lines extending from box are 10th and 90th
percentiles.
(TIF)
Table S1 Bivariate analysis of factors associated with
the outcome: TRAIL (T.1–T.3) .20 pg. SD: standard
deviation; *p value calculated with Mann Whitney if independent
variable is continuous, and with the two tailed exact Fisher test if
independent variable is dichotomous (p value,0.05 in bold). BMI:
Body Mass Index; CS: caesarean section; BE: base excess. **Fetal
distress if one of the following is true: Apgar at 1
st min. .5, Apgar
at 5
th min. ,7, pH,7.1, BE,212, need of resuscitation in first
30 min., admission to Intensive Neonatal Care.
(DOC)
Table S2 Biochemical measurements in the study
population (n=73). Values are given as median (mean6SD).
*p,0.01 with respect to T.1, T.2 and cord blood; 1 p,0.01 with
respect to T.1 and cord blood.
(DOC)
Table S3 Multivariate logistic regression analysis of
factors associated with the outcome: TRAIL delivery
(T.3)-first quartile. OR: Odds Ratio; CI: Confidence Interval;
*p value,0.05 in bold.
(DOC)
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